The U.S. government approved the use of Johnson & Johnson vaccine, which is said to be 100% effective in preventing serious illness.

Johnson & Johnson developed the Common Central Pneumonia (COVID-19) vaccine.

The U.S. Food and Drug Administration (FDA) recently approved an application for emergency use authorization for the Johnson & Johnson developed vaccine for common mesenteric pneumonia (COVID-19). At the same Time, the U.S. government announced that it has purchased 100 million doses of Johnson & Johnson’s vaccine. The vaccine is said to be 100% effective in preventing hospitalization and death due to infection with the CCP virus.

The FDA announced Saturday (Feb. 27) that it has authorized emergency use of the Janssen Covide-19 vaccine developed by Johnson & Johnson. The vaccine is intended for people 18 years of age and older.

This makes the Janssen vaccine the third vaccine officially approved for marketing in the United States, following the Pfizer-BioNTech and Moderna vaccines.

In a statement, Acting FDA Commissioner Janet Woodcock said the authorization expands the availability of the vaccine, which is the “best medical defense” against the CCP virus, to help combat an Epidemic that has claimed more than half a million American lives. The vaccine is the “best medical defense” against the Chinese Communist virus, helping to combat an epidemic that has claimed more than half a million American lives.

According to the Voice of America, Johnson & Johnson developed the vaccine in human trials on 44,000 people worldwide. The vaccine was 66% effective in protecting against moderate and severe CCP infection within 4 weeks of vaccination, and 100% effective in protecting against hospitalization and death due to CCP infection, with few serious side effects.

The Pfizer vaccine, which has previously been used on a large scale in Europe and the United States, is claimed to be 98.9% effective in preventing death from CCP pneumonia.

Typically, vaccinations are associated with varying degrees of side effects, including injection site pain, headache, fatigue and muscle aches.

According to the FDA, the vaccine was developed using another low virulence virus as the vector and adding some of the genetic instructions of the CCP virus. Once the vaccine enters human cells, it produces the typical CCLV protein, allowing the body’s immune system to recognize it.

This vaccine from Johnson & Johnson is a single dose vaccine (i.e., the vaccinator only needs one dose) and can be stored and shipped at normal refrigerator temperatures, making it easier to distribute the vaccine and therefore more conducive to widespread use worldwide.

The U.S. government says it has purchased 100 million doses of Johnson & Johnson vaccine and plans to distribute between 3 million and 4 million doses to the states this week. And Johnson & Johnson has pledged to provide 100 million doses of the vaccine to the U.S. by the end of June this year.

Previously, the U.S. government had ordered 600 million doses of Pfizer’s and Modena’s vaccine against the Chinese communist virus, which is expected to immunize the entire U.S. population by the end of July. Now that Johnson & Johnson’s vaccine is approved for use, it will certainly speed up the pace of vaccination across the United States.